Mycobacterium tuberculosis microbiologic and clinical treatment outcomes in a randomized trial of immediate versus CD4(+)-initiated antiretroviral therapy in HIV-infected adults with a high CD4(+) cell count

Clin Infect Dis. 2010 Aug 1;51(3):359-62. doi: 10.1086/654799.

Abstract

In a prospective randomized, controlled trial in Uganda comparing the efficacy of antiretroviral therapy during tuberculosis therapy with the efficacy of tuberculosis therapy alone in HIV-infected patients with tuberculosis who have a CD4(+) cell count >350 cells/microL, it was found that antiretroviral therapy did not accelerate microbiologic, radiographic, or clinical responses to tuberculosis therapy: 18% of participants had sputum smears positive for Mycobacterium tuberculosis after 5 months of tuberculosis therapy, despite having had negative culture results. Trial registration. ClinicalTrials.gov identifier: NCT00078247 .

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Anti-HIV Agents / administration & dosage*
  • Antiretroviral Therapy, Highly Active / methods*
  • Antitubercular Agents / administration & dosage*
  • CD4 Lymphocyte Count
  • Female
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • HIV Infections / immunology
  • Humans
  • Lung / pathology
  • Male
  • Mycobacterium tuberculosis / isolation & purification
  • Prospective Studies
  • Radiography, Thoracic
  • Sputum / microbiology
  • Treatment Outcome
  • Tuberculosis / drug therapy*
  • Tuberculosis / microbiology
  • Tuberculosis / pathology
  • Uganda

Substances

  • Anti-HIV Agents
  • Antitubercular Agents

Associated data

  • ClinicalTrials.gov/NCT00078247